Abstracts tagged "Systemic sclerosis"

Abstract Number: 1060 • 2019 ACR/ARP Annual Meeting
The Diversity and Community Metrics of the Esophageal Microbiome of SSc Patients
Monica Espinoza¹, Bhaven Mehta ², Yue Wang ³, Aileen Hoffman ⁴, Kathleen Aren ⁵, Mary Carns ⁶, Noelle Kosarek ², Tammara Wood ³, Monique Hinchcliff ⁷ and Michael Whitfield ⁸, ¹Dartmouth College, Hanover, NH, ²Dartmouth College, Hanover, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University, Chicago, ⁵Northwestern.edu, Chicago, ⁶Northwestern University, Hanover, ⁷Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT, ⁸Geisel School of Medicine at Dartmouth College, Biomedical Data Science at Dartmouth College, Hanover
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by fibrosis and inflammation. Multiple organ systems are affected including the skin, gastrointestinal tract, vasculature, and…
Abstract Number: 1647 • 2019 ACR/ARP Annual Meeting
The Collaborative National Quality and Efficacy Registry for Scleroderma: Data Completion Outcomes from a Multicenter United States Cohort Using Guideline-Based Registry Practices
Victoria Shanmugam¹, Tracy Frech ², Virginia Steen ³, Laura Hummers ⁴, Ami Shah ⁵, Elana Bernstein ⁶, Dinesh Khanna ⁷, Jessica Gordon ⁸, Flavia Castelino ⁹, Lorinda Chung ¹⁰, Faye Hant ¹¹, Emily Startup ¹², John VanBuren ¹², Luke Evnin ¹³ and Shervin Assassi ¹⁴, ¹George Washington University, Georgetown, DC, ²Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ³Georgetown University, Washington, D.C., USA, Georgetown, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ⁵Johns Hopkins Hospital, Baltimore, MD, ⁶Division of Rheumatology, Columbia University, New York, NY, ⁷Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁸Hospital for Special Surgery, New York, NY, ⁹Harvard University, Boston, MA, ¹⁰Stanford University, Palo Alto, CA, ¹¹Medical University of South Carolina, Charleston, SC, ¹²University of Utah, Salt Lake City, UT, ¹³Scleroderma Research Foundation, San Francisco, CA, ¹⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX
Background/Purpose: The Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma is a multicenter US-based longitudinal study of patients with systemic sclerosis (SSc) within 5…
Abstract Number: 2262 • 2019 ACR/ARP Annual Meeting
Evaluation of Illness Perception in Systemic Sclerosis Patients with Pulmonary Involvement
Bruna Giusto Bunjes¹, Percival Degrava Sampaio-Barros ² and Ana Paula Luppino-Assad ³, ¹1- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil., Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil., Sao Paulo, Brazil
Background/Purpose: Lung disease is the current leading cause of death and the most common severe complication of systemic sclerosis (SSc), causing a significant adverse impact in quality of…
Abstract Number: 2607 • 2019 ACR/ARP Annual Meeting
Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis
Robert Fairchild¹, Melody Chung ¹, Laurel Sharpless ¹, Shufeng Li ² and Lorinda Chung ¹, ¹Stanford University, Palo Alto, CA, ²Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA
Background/Purpose: Systemic Sclerosis (SSc) is a progressive fibrotic and vascular disease affecting multiple organs. Calcinosis cutis in SSc is characterized by calcium deposition in the…
Abstract Number: 718 • 2019 ACR/ARP Annual Meeting
Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions
Håvard Fretheim¹, Øyvind Midtvedt ², Torhild Garen ², Arne Kristian Andreassen ², Einar Gude ², Øyvind Molberg ³ and Anna Maria Hoffmann-Vold ⁴, ¹Oslo University Hospital, Oslo, ²Oslo University Hospital, Oslo, Norway, ³University Hospital Oslo, Oslo, Norway, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Pre-capillary pulmonary hypertension (PH) is a feared complication in patients with systemic sclerosis (SSc) and is associated with high mortality despite new treatment options.…
Abstract Number: 864 • 2019 ACR/ARP Annual Meeting
Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Robert Spiera ¹, Dana Orange ², Cynthia Magro ³, Yaxia Zhang ⁴, Jackie Finik ⁵ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Weill Cornell Medicine, New York, ⁴Hospital for Special Surgery, New York, ⁵Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The Combined Response Index in Systemic Sclerosis (CRISS) is a composite outcome measure provisionally endorsed by the American College of Rheumatology for use in…
Abstract Number: 1063 • 2019 ACR/ARP Annual Meeting
Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis
David Fox¹, Michael Whitfield ², Veronica Berrocal ³, Steven K. Lundy ⁴, Phillip Campbell ⁵, Stephanie Rasmussen ⁵, Ray Ohara ⁶, Alexander Stinson ⁶, Evan Wiewiora ⁷, Cathie Spino ⁷, Erica Bush ⁸, Daniel Furst ⁹, Shiv Pillai ¹⁰ and Dinesh Khanna ¹¹, ¹Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI, ²Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hannover, NH, ³Department of Biostatistics, School of Publich Health, University of Michigan, Ann Arbor, MI, ⁴TBD, Seattle, WA, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁶Washington University, St. Louis, MO, ⁷Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, ⁸Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁹University of California at Los Angeles, Los Angeles, CA, ¹⁰Ragon Institude of MGH, MIT and Harvard, Charlestown, MA, ¹¹Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor
Background/Purpose: Background: In a randomized controlled trial of abatacept in early diffuse systemic sclerosis (Khanna D, et al ACR 2018), we observed early clinical flares…
Abstract Number: 1648 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
Boyang Zheng¹, Mianbo Wang ², Marvin Fritzler ³, May Choi ³, Murray Baron ⁴ and Marie Hudson ⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Jewish General Hospital, McGill University, Montreal, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is frequent manifestation and a leading cause of mortality in systemic sclerosis (SSc). Some SSc-related autoantibodies (aAbs), especially anti-topoisomerase I…
Abstract Number: 2588 • 2019 ACR/ARP Annual Meeting
Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations
Amélie Leurs ¹, Sylvain Dubucquoi ¹, François Machuron ¹, Maité Balden ¹, Florence Renaud ¹, Stéphanie Rogeau ¹, Benjamin Lopez ², Marc LAMBERT ³, Sandrine Morell-Dubois ⁴, Hélène Maillard ⁴, Hélène Behal ¹, Eric Hachulla ⁵, David Launay ¹ and Vincent Sobanski¹, ¹CHU Lille, Lille, France, ²Institute of Immunology, CHU Lille, University of Lille, Lille, France, ³Lille University Hospital, Lille, France, ⁴Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed…
Abstract Number: 2609 • 2019 ACR/ARP Annual Meeting
Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy
Victoria Flower¹, Shaney Barratt ², Darren Hart ³, Amanda Mackenzie ⁴, Jacqueline Shipley ³, Stephen Ward ⁴ and John Pauling ¹, ¹Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, ²North Bristol NHS Trust, Bristol, England, United Kingdom, ³Department of Clinical Measurement, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, ⁴Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, England, United Kingdom
Background/Purpose: The anti-angiogenic isoform of Vascular Endothelial Growth Factor-A (VEGF-A165b) has been implicated in Systemic sclerosis (SSc) vasculopathy. High frequency ultrasound (HFUS) is a novel…
Abstract Number: 719 • 2019 ACR/ARP Annual Meeting
Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth
Hanyan Zou¹, Giada De Palma ², Premysl Bercik ², Elena Verdu ², Karen Beattie ² and Maggie Larche ², ¹McMaster University, Mississauga, ON, Canada, ²McMaster University, Hamilton, ON, Canada
Background/Purpose: The gastrointestinal tract (GIT) is commonly involved in SSc with up to 98% of patients reporting GIT manifestations. Small intestinal bacterial overgrowth (SIBO) is…
Abstract Number: 865 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert Spiera¹, Laura Hummers ², Lorinda Chung ³, Tracy Frech ⁴, Robyn Domsic ⁵, Vivien Hsu ⁶, Daniel Furst ⁷, Jessica Gordon ¹, Madeline Myers ⁸, Robert W Simms ⁹, Elizabeth Lee ¹⁰, Scott Constantine ¹⁰, Nancy Dgetluck ¹⁰, Bradley Bloom ¹⁰ and Barbara White ¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, USA, Baltimore, MD, ³Stanford, Palo Alto, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, ⁷University of California, Los Angeles, CA, ⁸University of Texas, Houston, Houston, TX, ⁹Boston University, Boston, MA, ¹⁰Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models…
Abstract Number: 1067 • 2019 ACR/ARP Annual Meeting
Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis
Yiwei Yuan¹, Yue Wang ², Patricia Pioli ³ and Michael Whitfield ⁴, ¹Geisel School of Medicine at Dartmouth, Hanover, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth College, Hanover, ⁴Geisel School of Medicine at Dartmouth College, Biomedical Data Science at Dartmouth College, Hanover
Background/Purpose: Systemic sclerosis (SSc; scleroderma) is a rare, heterogenous autoimmune disease characterized by skin fibrosis, vasculopathy and internal organ involvement. SSc patients can be divided…
Abstract Number: 1649 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Holly LeClair ², Philip Clements ², Daniel Furst ⁴, Robert Elashoff ² and Dinesh Khanna ⁵, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of California, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). The majority of studies investigating novel therapies for…
Abstract Number: 2590 • 2019 ACR/ARP Annual Meeting
Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis
Anita Chandrasekaran¹, Imran Omar ², Zhicheng Fu ³, Shangping Ren ³ and Monique Hinchcliff ¹, ¹Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³San Diego State University, Department of Computer Science, San Diego, CA
Background/Purpose: Calcinosis cutis, found in both systemic sclerosis (SSc) and juvenile dermatomyositis patients, can be extensive and debilitating. Potential treatments have been identified, but a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].